The Chicago Entrepreneur

Raymond James: Small-cap biotechs on track for ‘worst 12-month run’ in decades

Small-cap biotechnology companies are on track for the worst 12 months in more than 15 years when compared with their large-cap biotech peers, according to Raymond James analysts. Small-cap biotechs outperformed large-cap biotechs in only one month-August-out of the past 12 months. “The current confluence of factors negatively impacting the biotech sector has been staggering,” the analysts wrote in a note on Tuesday. “Biotech sector quant factors are suggesting we are at a cyclical low only matched by the [global financial crisis].” Over the past year, the iShares Biotechnology ETF is down 22.7%, and the SPDR S&P Biotech ETF has tumbled 44.5%, while the broader S&P 500 SPX has declined 10.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post Apellis shares jump 6% after the company announces new data for its geographic atrophy drug
Next post Biogen’s stock gains after sharing longer term data for its Alzheimer’s disease drug

No Shopify connection found. Please double check your API keys.